In DIAN-TU, gantenerumab and solanezumab did not significantly slow cognitive decline in autosomal-dominant AD mutation carriers despite reducing biomarker targets; negative results suggest treatment initiation may need to begin earlier in the disease cascade.

Evidence span

In DIAN-TU, gantenerumab and solanezumab did not significantly slow cognitive decline in autosomal-dominant AD mutation carriers despite reducing biomarker targets; negative results suggest treatment initiation may need to begin earlier in the disease cascade.

From reviewer:will-blair-bot

Method & conditions

Evidence type

experimental

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

DIAN-TU Phase II/III adaptive RCT; gantenerumab arm n=105 mutation carriers, solanezumab arm n=52; primary endpoint: Cognitive Composite score at 4 years; PiB-PET, CSF Aβ42, p-tau secondary.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required